


What is claimed is:

1. A silyl linker for use in the solid-phase synthesis of nucleic acid, comprised of a compound of the general formula or its ester or salt:



wherein each of R1 and R2 is an alkyl or aryl group, and (A) represents a spacer moiety.

2. The compound according to Claim 1 wherein the spacer moiety (A) is an alkylene group represented by the formula: $-(\text{CH}_2)_n-$
10 wherein "n" is a natural number.
3. The compound according to Claim 2 wherein "n" is 2-18.
4. The compound according to Claim 2 or 3 wherein the alkylene group has at least one ether or thioether bond.
5. The compound according to any one of Claims 1 to 4 wherein
15 R1 and R2 are an alkyl group having 1 to 5 carbon atoms.
6. The compound according to any one of Claims 1 to 4 wherein the aryl group of R1 and R2 has a substituent of alkyl, nitro, cyano, halogeno or methoxy group.
7. The compound according to any one of Claims 1 to 6 wherein
20 a benzene ring structure has a substituent.
8. The compound according to Claim 7 wherein the substituent of the benzene ring structure is selected from the group consisting of alkyl having 1 to 4 carbon atoms, halogeno, nitro, cyano and methoxy groups.
- 25 9. A 3'-end nucleoside unit having the compound according to any one of Claims 1 to 8 linked via an oxygen atom to the

3-position of a sugar of the nucleoside or its derivative.

10. The 3'-end nucleoside unit according to Claim 9 wherein a base constituting the nucleoside is thymine.

11. The compound according to Claim 10 which is

5 5'-O-(4,4'-dimethoxytrityl)-thymidine-3'-O-diisopropylsilyl-4-benzoylaminobutanoic acid triethylammonium.

12. A solid-phase support having the 3'-end nucleoside unit according to Claim 9 introduced thereon.

13. The solid-phase support according to Claim 12 having the
10 3'-end nucleoside unit at a ratio of 20-30 $\mu\text{mol/g}$.

14. The solid-phase support according to Claim 12 or 13, which is HCP solid-phase support.

15. A method for synthesis of a nucleic acid oligomer with the use of the solid-phase support according Claims 12, 13 or

15 14.

16. The method according to Claim 15 wherein the nucleic acid oligomer contains a modified base.